These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9487240)

  • 1. Sulfonylureas and ischemic heart disease.
    Matz R
    Arch Intern Med; 1998 Feb; 158(4):411-2. PubMed ID: 9487240
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
    Schotborgh CE; Wilde AA
    Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular effects of conventional sulfonylureas and glimepiride.
    Geisen K; Végh A; Krause E; Papp JG
    Horm Metab Res; 1996 Sep; 28(9):496-507. PubMed ID: 8911987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
    Mocanu MM; Maddock HL; Baxter GF; Lawrence CL; Standen NB; Yellon DM
    Circulation; 2001 Jun; 103(25):3111-6. PubMed ID: 11425777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The sulfonylurea controversy: more questions from the heart.
    Brady PA; Terzic A
    J Am Coll Cardiol; 1998 Apr; 31(5):950-6. PubMed ID: 9561992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
    Tosaki A; Szerdahelyi P; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glimepiride and glibenclamide, inhibitors of ATP-dependent K(+)-channel, on ischaemia-reperfusion induced arrhythmias in rats.
    Bozdogan O; Leprán I; Papp JG
    Acta Physiol Hung; 1996; 84(3):265-6. PubMed ID: 9219599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.
    Aronson D; Mittleman MA; Burger AJ
    Pacing Clin Electrophysiol; 2003 May; 26(5):1254-61. PubMed ID: 12765455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of sulphonylurea derivatives.
    Smits P
    Diabetologia; 1997 Jul; 40 Suppl 2():S160-1. PubMed ID: 9248730
    [No Abstract]   [Full Text] [Related]  

  • 11. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
    Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylurea and the Heart: Theoretically a Compounded Question from a Pathophysiological Perspective.
    Farahani P
    J Popul Ther Clin Pharmacol; 2016 Sep; 23(3):e193-e195. PubMed ID: 27783474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
    Tosaki A; Engelman DT; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preconditioning modulates susceptibility to ischemia-induced arrhythmias in the rat heart: the role of alpha-adrenergic stimulation and K(ATP) channels.
    Ravingerová T; Pancza D; Ziegelhoffer A; Styk J
    Physiol Res; 2002; 51(2):109-19. PubMed ID: 12108920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic and other effects of sulphonylurea drugs on the heart.
    Végh A; Papp JG
    Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S43-53. PubMed ID: 8864640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart.
    Legtenberg RJ; Houston RJ; Oeseburg B; Smits P
    Eur J Pharmacol; 2001 May; 419(1):85-92. PubMed ID: 11348634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.
    Riveline JP; Danchin N; Ledru F; Varroud-Vial M; Charpentier G
    Diabetes Metab; 2003 Jun; 29(3):207-22. PubMed ID: 12909809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin secretion and its modulation by antiarrhythmic and sulfonylurea drugs.
    Horie M; Ishida-Takahashi A; Ai T; Nishimoto T; Tsuura Y; Ishida H; Seino Y; Sasayama S
    Cardiovasc Res; 1997 Apr; 34(1):69-72. PubMed ID: 9217874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-sensitive potassium channels, transmural ischemia and the ECG implications for the non-insulin dependent diabetic patient?
    Wilde AA
    Cardiovasc Res; 1996 May; 31(5):688-90. PubMed ID: 8763397
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetes mellitus and ischemic cardiopathy: potential effects of the use of sulfonylureas].
    Gonçalves JV; Caldeira J
    Rev Port Cardiol; 2001 Apr; 20(4):439-45. PubMed ID: 11433889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.